趋化因子CXCL5及受体CXCR2在肝细胞癌中的表达及其与临床预后的关系

Expression of CXCL5 and CXCR2 in Hepatocellular Carcinoma and Its Relationship with Prognosis

[目的]探讨趋化因子CXCL5及其受体CXCR2与肝细胞癌(HCC)的临床病理特征和术后复发的关系。[方法]根据随访结果,分为早期复发组、非早期复发组和无复发组。运用荧光定量PCR检测3组肝癌患者组织中CXCL5和CXCR2的相对表达量。[结果]CXCL5在早期复发组的相对表达量高于无复发组(P=0.011);与临床分期和HBsAg状态有关(P<0.05)。CXCR2在早期复发组的相对表达量高于无复发组(P<0.001),同时高于非早期复发组(P=0.005);与临床分期、肿瘤直径和HBsAg状态有关(P<0.05)。CXCL5-CXCR2共同高表达患者的5年累积生存率明显低于其他患者(P=0.005)。[结论]CXCL5和CXCR2在肝癌中高表达,并与临床病理特征和术后复发有关。CXCL5和CXCR2有望成为肝癌术后预后判断的指标。

[Purpose] To investigate the expression of chemokine CXCL5 and its receptor CXCR2 in hepatocellular carcinoma（HCC） and its relationship with clinical pathological features and prognosis. [Methods] Based on the results of follow-up,all patients were divided into early relapse group,non-early relapse group and relapse-free group. The relative expression of CXCL5 and CXCR2 in the three groups of HCC patients was detected by quantitative PCR.[Results] The relative expression of CXCL5 in early relapse group was higher than that in relapse-free group（P=0.011）,and it related to clinical stages and status of HBsAg（P〈0.05）. The relative expression of CXCR2 in early relapse group was higher than that in relapse-free group（P〈0.001） and non-early relapse group（P=0.005）,and it related to clinical stages,diameter of tumor and status of HBsAg（P〈0.05）.5-year cumulative survival rate in patients with co-expression of CXCL5-CXCR2 was significantly lower than that in other patients（P=0.005）. [Conclusion] The expression of CXCL5 and CXCR2 in HCC relates to clinico-pathological characteristics and postoperative relapse. Therefore,CXCL5 and CXCR2 can be expected to become a potential index for postoperative prognosis of HCC.